Aurinia Pharmaceuticals Inc. (AUPH)

NASDAQ: AUPH · IEX Real-Time Price · USD
15.12
0.47 (3.21%)
Jan 28, 2022 2:07 PM EST - Market open
Market Cap1.96B
Revenue (ttm)72.23M
Net Income (ttm)-170.20M
Shares Out129.67M
EPS (ttm)-1.22
PE Ration/a
Forward PE434.78
Dividendn/a
Ex-Dividend Daten/a
Volume3,055,787
Open14.85
Previous Close14.65
Day's Range14.12 - 15.77
52-Week Range9.72 - 33.97
Beta0.69
AnalystsBuy
Price Target31.56 (+108.7%)
Earnings DateFeb 22, 2022

About AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

IndustryBiotechnology
IPO DateJan 26, 1999
CEOPeter Greenleaf
Employees294
Stock ExchangeNASDAQ
Ticker SymbolAUPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price forecast is 31.56, which is an increase of 108.73% from the latest price.

Price Target
$31.56
(108.73% upside)
Analyst Consensus: Buy

News

My 3 Top Biopharma Stock Picks for 2022

These three stocks are poised for a major breakout in 2022.

Other symbols:AXSMCRDF
2 weeks ago - The Motley Fool

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual inve...

3 weeks ago - Business Wire

Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of Lupkynis (voclosporin) for active lupus nep...

1 month ago - Benzinga

The 2 Nasdaq Biotech Stocks to Watch Thursday

The market is getting close to new highs again, but choppy performance is likely.

Other symbols:RETA
1 month ago - The Motley Fool

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Tr...

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course ...

1 month ago - Business Wire

8 Beaten-Down Pharmaceutical Stocks That Could Skyrocket In 2022

These eight stocks could rebound nicely over the next year and beyond.

1 month ago - The Motley Fool

Aurinia (AUPH) Stock Up on Potential Acquisition Rumors

Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.

1 month ago - Zacks Investment Research

Why Aurinia Pharmaceuticals Stock Bolted Higher Today

Renewed buyout speculation has investors piling into this biotech stock today.

1 month ago - The Motley Fool

AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today

Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). The post AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Sh...

Other symbols:NVS
1 month ago - InvestorPlace

AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today

Aurinia Pharma (AUPH) stock is taking a beating on Monday following a filing with the SEC after markets closed on Friday. The post AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Toda...

2 months ago - InvestorPlace

Here's Why Aurinia Pharmaceuticals Is Falling Today

The company's recently filed unlimited shelf registration statement is making shareholders queasy.

2 months ago - The Motley Fool

Why Aurinia Pharmaceuticals Stock Crashed in After-Hours Trading on Friday

A $250 mixed shelf offering isn't sitting well with the biotech's shareholders.

2 months ago - The Motley Fool

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies ...

2 months ago - Business Wire

Is Bristol Myers Squibb's Reported Acquisition of Aurinia a Smart Move?

It could be.

Other symbols:BMY
2 months ago - The Motley Fool

Here's Why Bristol Myers Squibb Can't Miss Out on Aurinia Pharmaceuticals

The biopharma's takeover bid has failed to materialize after nearly two weeks. Here's what might be going on.

Other symbols:BMY
2 months ago - The Motley Fool

Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Lags Revenue Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -25.81% and -0.24%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Aurinia Pharmaceuticals: Q3 Earnings Insights

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

2 months ago - Benzinga

Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates

VICTORIA, British Columbia--(BUSINESS WIRE)--AURINIA REPORTS THIRD QUARTER AND NINE MONTHS 2021 FINANCIAL RESULTS AND COMPANY UPDATES

2 months ago - Business Wire

Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Trea...

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of auto...

2 months ago - Business Wire

Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that it will release its third quarter 2021 financial results on Wednesday, Novem...

3 months ago - Business Wire

Aurinia Pharmaceuticals to Present Five Abstracts at ASN Kidney Week 2021 and ACR Convergence 2021

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of auto...

3 months ago - Business Wire

Aurinia (AUPH) Surges 6.6%: Is This an Indication of Further Gains?

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th...

3 months ago - Zacks Investment Research

2 Biotech Stocks That Could Go Parabolic This Week

These stocks could soon take flight.

Other symbols:OCGN
3 months ago - The Motley Fool

Why Aurinia Pharmaceuticals Stock Is Blasting Higher Today

The biotech is reportedly in buyout talks with Bristol Myers Squibb.

3 months ago - The Motley Fool